Dr. Barad joined the Pain Medicine faculty in 2008. Dr. Barad is a board-certified Neurologist, Headache and Pain physician. Her primary focus is helping patients with head and facial pain. She has collaborated in creating a cross-disciplinary headache center and is the co-director of the Stanford Orofacial Pain Program. She is the Program Director for the Pain Fellowship.

Originally from Colorado, Dr. Barad completed her undergraduate studies in biology and honors liberal arts at the University of Texas, Austin, TX. She earned her medical degree from Stanford University School of Medicine and completed her internship at Santa Clara Valley Medical Center in San Jose, CA. She completed her Neurology residency and Pain Medicine fellowship at Stanford Hospital. Then she pursued a two-year research training fellowship studying neuroimaging and pain in the lab of Dr. Sean Mackey at Stanford. This research involved using functional magnetic resonance imaging (fMRI) to image the brain activation of a patient in chronic pain and train the patient to modify both the activation and experience of pain.

Clinical Focus

  • Pain Management
  • Headache Disorders
  • Orofacial Pain
  • Pain Medicine

Academic Appointments

Administrative Appointments

  • Program Director, Pain Medicine Fellowship (2019 - Present)
  • Co-Director Orofacial Pain Program, Stanford Hospital and Clinics (2014 - Present)

Boards, Advisory Committees, Professional Organizations

  • Director of Headache and Facial Pain Special Interest Group, American Academy of Pain Medicine (2019 - Present)
  • Board of Directors, American Interventional Headache Society (2019 - Present)
  • Associate Editor Headache and Facial Pain Section, Pain Medicine (2021 - Present)
  • Director at Large, Association of Pain Program Directors (2021 - Present)

Professional Education

  • Board Certification: American Board of Psychiatry and Neurology, Pain Medicine (2020)
  • Medical Education: Stanford University School of Medicine (2003) CA
  • Fellowship: Stanford University Pain Management Fellowship (2008) CA
  • Residency: Stanford University Neurology Residency (2007) CA
  • Internship: Santa Clara Valley Medical Center Dept of Medicine (2004) CA
  • Board Certification: United Council for Neurologic Subspecialties, Headache Medicine (2012)
  • Board Certification, United Council for Neurologic Subspecialites, Headache (2012)
  • Board Certification: American Board of Psychiatry and Neurology, Neurology (2008)

Community and International Work

  • National Take Back Day, Redwood City


    Return of unused medications

    Partnering Organization(s)

    Redwood City Police Departmet

    Populations Served

    Redwood City community


    Bay Area

    Ongoing Project


    Opportunities for Student Involvement


Current Research and Scholarly Interests

My current research interests involve novel treatment paradigms for challenging pain problems such as orofacial pain, trigeminal neuralgia and low pressure headaches. I am also interested in migraine and trigeminal autonomic cephalgias and their intersection with chronic pain.

Clinical Trials

  • Trial for Treatment Refractory Trigeminal Neuralgia Recruiting

    The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.

    View full details

Graduate and Fellowship Programs

  • Pain Management (Fellowship Program)

All Publications

  • Chronic disabling postpartum headache after unintentional dural puncture during epidural anaesthesia: a prospective cohort study. British journal of anaesthesia Ansari, J. R., Barad, M., Shafer, S., Flood, P. 2021; 127 (4): 600-607


    BACKGROUND: Unintentional dural puncture with an epidural needle complicates approximately 1% of epidural anaesthetics and causes an acute headache in 60-80% of these patients. Several retrospective studies suggest an increased risk of chronic headache. We assessed the relationship between unintentional dural puncture and chronic disabling headache, defined as one or more functionally limiting headaches within a 2-week interval ending 2, 6, and 12 months postpartum.METHODS: In this prospective observational study, parturients who experienced unintentional dural puncture were matched 1:4 with control patients. Patients completed questionnaires regarding characteristics of headache and back pain pre-pregnancy, during pregnancy, immediately postpartum, and at 2, 6, and 12 months postpartum. The primary outcome was prevalence of disabling headache in the past 2 weeks, assessed at 2 months postpartum. Secondary outcomes included prevalence and characteristics of headache and back pain at these time points.RESULTS: We enrolled 99 patients. At 2 and 6 months postpartum, the prevalence of disabling headache was greater among patients with unintentional dural puncture than matched controls (2 months, 74% vs 38%, relative risk 1.9, 95% confidence interval 1.2-2.9, P=0.009; 6 months, 56% vs 25%, relative risk 2.1, 95% confidence interval 1.1-4.0, P=0.033). There was no difference in the prevalence of back pain at any time point.CONCLUSIONS: Our prospective trial confirms retrospective studies that chronic headache is more prevalent among women who experienced unintentional dural puncture compared with controls who received uncomplicated neuraxial anaesthesia. This finding has implications for the. patient consent process and recommendations for long-term follow-up of patients who experience unintentional dural puncture.

    View details for DOI 10.1016/j.bja.2021.05.020

    View details for PubMedID 34548152

  • The Pain Medicine Fellowship Telehealth Education Collaborative. Pain medicine (Malden, Mass.) Hascalovici, J., Kohan, L., Spektor, B., Sobey, C., Meroney, M., Anitescu, M., Barad, M., Steinmann, A., Vydyanathan, A., Wahezi, S. 2021

    View details for DOI 10.1093/pm/pnab251

    View details for PubMedID 34402913

  • Percutaneous Interventional Strategies for Migraine Prevention: A Systematic Review and Practice Guideline. Pain medicine (Malden, Mass.) Barad, M., Ailani, J., Hakim, S. M., Kissoon, N. R., Schuster, N. M. 2021


    OBJECTIVE: To systematically evaluate the efficacy and effectiveness of percutaneous interventional treatments for prevention of migraine through a qualitative and (when possible) quantitative analysis.METHODS: An expert panel was asked to develop recommendations for the multidisciplinary preventive treatment of migraine, including interventional strategies. The committee conducted a systematic review and (when evidence was sufficient) a meta-analytic review using GRADE criteria and the modified Cochrane risk of bias analysis available in the Covidence data management program. Clinical questions addressed adults with migraine who should be offered prevention. Examined outcomes included headache days, acute medication use, and functional impairment. Acute management of migraine was outside the scope of this guideline.RESULTS: The committee screened 1195 studies and assessed 352 by full text, yielding 16 randomized controlled trials that met inclusion criteria.RECOMMENDATIONS/CONCLUSIONS: As informed by evidence related to the preselected outcomes, adverse event profile, cost, and values and preferences of patients, onabotulinumtoxinA received a strong recommendation for chronic migraine prevention and a weak recommendation against use for episodic migraine prevention. Greater occipital nerve blocks received a weak recommendation for chronic migraine prevention. For greater occipital nerve block, steroid received a weak recommendation against use vs local anesthetic alone. Occipital nerve with supraorbital nerve blocks, sphenopalatine ganglion blocks, cervical spine percutaneous interventions, and implantable stimulation all received weak recommendations for chronic migraine prevention. The committee found insufficient evidence to assess trigger point injections in migraine prevention and highly discouraged use of intrathecal medication.

    View details for DOI 10.1093/pm/pnab236

    View details for PubMedID 34382092

  • Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study. Headache Barad, M. J., Sturgeon, J. A., Hong, J., Aggarwal, A. K., Mackey, S. C. 2021


    OBJECTIVE: Chronic overlapping pain conditions (COPCs) represent a co-aggregation of widespread pain disorders. We characterized differences in physical and psychosocial functioning in patients with chronic migraine (CM) and those with CM and COPCs.BACKGROUND: Patients with CM and COPCs have been identified as a distinct subgroup of patients with CM, and these patients may be vulnerable to greater symptom severity and burden.METHODS: Data were extracted from Collaborative Health Outcomes Information Registry (an open-source learning health-care system), completed at the patients' first visit at a large tertiary care pain management center and electronic medical records. In 1601 patients with CM, the number of non-cephalic areas of pain endorsed on a body map was used to examine the differences in pain, physical and psychosocial function, adverse life experience, and health-care utilization.RESULTS: Patients endorsing more body map regions reported significantly worse symptoms and function across all domains. Scored on a t-score metric (mean = 50, SD = 10), endorsement of one additional body map region corresponded with a 0.69-point increase in pain interference (95% CI = 0.55, 0.82; p<0.001; Cohen's f=0.328), 1.15-point increase in fatigue (95% CI = 0.97, 1.32; p<0.001; Cohen's f=0.432), and 1.21-point decrease in physical function (95% CI = -1.39, -1.03; p<0.001; Cohen's f=0.560). Patients with more widespread pain reported approximately 5% more physician visits (95% CI = 0.03, 0.07; p<0.001), and patients reporting adverse life events prior to age 17 endorsed 22% more body map regions (95% CI = 0.11, 0.32; p<0.001).CONCLUSIONS: Patients with CM and other overlapping pain conditions as noted on the body map report significantly worse pain-related physical function, psychosocial functioning, increased health-care utilization, and greater association with adverse life experiences, compared with those with localized CM. This study provides further evidence that patients with CM and co-occurring pain conditions are a distinct subgroup of CM and can be easily identified through patient-reported outcome measures.

    View details for DOI 10.1111/head.14129

    View details for PubMedID 34184263

  • Did she have an epidural? The long-term consequences of postdural puncture headache and the role of unintended dural puncture. Headache Barad, M., Carroll, I., Reina, M. A., Ansari, J., Flood, P. 2021


    This narrative literature review examines the long-term impact of postdural puncture headache (PDPH) in postpartum women following an unintended dural puncture (UDP) with a large bore needle commonly used for epidural catheter placement. It seeks to bridge the knowledge gap for the neurologist as to the mounting body of obstetric anesthesia literature on the development of chronic headache after PDPH with this unique needle.Headache is the most common complication of dural puncture, and the risk is greatest in the parturient population. Preexisting risk factors for this population include youth and sex, and after UDP with a large bore needle, almost 70%-80% report a headache. Additionally, there appears to be a significant cohort who experience long-term, persistent headache after UDP.We performed a narrative review of literature using PubMed, searching terms that included long-term follow-up after UDP with a large bore needle in the postpartum population.In women who had UDP with a large bore needle used for epidural catheter placement at delivery, the rate of chronic debilitating headache is around 30% in the months following delivery and may persist for up to a year or longer.Based on the existing literature, we have mounting evidence that UDP with the large bore needle used to place an epidural catheter should be understood as a high-risk inciting event for the development of long-term headaches not simply a high risk of acute PDPH. Additionally, consideration should be given to stratifying the etiology of PDPH, based on needle type, and recognizing the entity of chronic PDPH, thus allowing for improvements in research and diagnosis.

    View details for DOI 10.1111/head.14221

    View details for PubMedID 34570902

  • Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures. Headache Holsteen, K. K., Hittle, M., Barad, M., Nelson, L. M. 2020


    OBJECTIVE: To develop and internally validate a multivariable predictive model for days with new-onset migraine headaches based on patient self-prediction and exposure to common trigger factors.BACKGROUND: Accurate real-time forecasting of one's daily risk of migraine attack could help episodic migraine patients to target preventive medications for susceptible time periods and help decrease the burden of disease. Little is known about the predictive utility of common migraine trigger factors.METHODS: We recruited adults with episodic migraine through online forums to participate in a 90-day prospective daily-diary cohort study conducted through a custom research application for iPhone. Every evening, participants answered questions about migraine occurrence and potential predictors including stress, sleep, caffeine and alcohol consumption, menstruation, and self-prediction. We developed and estimated multivariable multilevel logistic regression models for the risk of a new-onset migraine day vs a healthy day and internally validated the models using repeated cross-validation.RESULTS: We had 178 participants complete the study and qualify for the primary analysis which included 1870 migraine events. We found that a decrease in caffeine consumption, higher self-predicted probability of headache, a higher level of stress, and times within 2days of the onset of menstruation were positively associated with next-day migraine risk. The multivariable model predicted migraine risk only slightly better than chance (within-person C-statistic: 0.56, 95% CI: 0.54, 0.58).CONCLUSIONS: In this study, episodic migraine attacks were not predictable based on self-prediction or on self-reported exposure to common trigger factors. Improvements in accuracy and breadth of data collection are needed to build clinically useful migraine prediction models.

    View details for DOI 10.1111/head.13960

    View details for PubMedID 33022773

  • Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain. Regional anesthesia and pain medicine Barad, M., Sturgeon, J. A., Fish, S., Dexter, F., Mackey, S., Flood, P. D. 2019; 44 (6): 660–68


    BACKGROUND: The phase III research evaluating migraine prophylaxis therapy (PREEMPT) protocol was developed in low-risk migraine patients. We studied longitudinal response to treatment in a sequential retrospective observational cohort to evaluate predictors of effectiveness in patients with multiple overlapping pain syndromes treated in a quaternary pain management clinic.METHODS: We evaluated indicators of individual response in 402 consecutive chronic migraine patients who provided demographic information and used the Collaborative Health Outcomes Information Registry.RESULTS: The patients were middle aged 47 (38-56) median (IQR) years old and 83% women. They reported multiple complex pain problems with 11 (6-18) regions represented on a pain body map. Evaluated with National Institutes of Health Patient-Reported Outcomes Measurement Information System measures, they reported higher scores for sleep impairment and disturbance, anxiety, depression, fatigue, pain behavior, pain interference and worse function and satisfaction with social roles compared with the general US population; p<0.001for all domains. Within 120days of treatment, 62% of patients reported reduced headache frequency. The best multivariable model developed for prediction of reduced headache frequency in response to treatment included lower treatment number, lower pain interference score, and less depression (p=0.001, 0.002, and 0.009). Depression may have been an obstacle to successful treatment; there was no association between depression score and number of treatments (p=0.54).CONCLUSIONS: Our findings point to the importance of identifying and addressing pain interference and depression early in chronic migraine management and, more broadly, highlights the importance of multidisciplinary evaluation and treatment in chronic migraine.

    View details for DOI 10.1136/rapm-2018-100196

    View details for PubMedID 31101743

  • Treatment Strategies for the Opioid-Dependent Patient (vol 21, 45, 2017) CURRENT PAIN AND HEADACHE REPORTS Teckchandani, S., Barad, M. 2018; 22 (3): 21


    The original version of this article contains an error in the gender listing of the first author in the Conflict of Interest statement.

    View details for PubMedID 29511854

  • Treatment Strategies for the Opioid-Dependent Patient CURRENT PAIN AND HEADACHE REPORTS Teckchandani, S., Barad, M. 2017; 21 (11): 45


    This review is intended to help the headache physician think through and plan for management issues concerning the use of opioids. We ask the headache physician to consider if there are instances where prescribing or continuing prescriptions of opiates is plausible, and if so, how can the physician proceed as safely as possible. Our goal is to start a conversation regarding the inevitable encounter with a patient on opiates or requesting opiates.The use of opiates in our society has reached a crisis in staggering death and addiction rates. Recent guideline published by the CDC can assist us in developing an algorithmic approach towards opiate use. Recent advances in addiction medicine can also assist us in protecting our patients. Every headache physician will undoubtedly encounter patients on opiates. There still are appropriate reasons to treat patients with opiates. Every headache physician may need to prescribe opiates and they may be indicated. It is important to learn the correct way to approach, manage, and treat patients on opiates.

    View details for PubMedID 28932964

  • Effect of Educating the Primary Care Physician About Headache to Help Reduce "Trivial" Referrals and Improve the Number and Quality of "Substantial" Referrals that Truly Need Subspecialty Headache Medicine Care. Current treatment options in neurology Cowan, R., Barad, M. 2017; 19 (7): 25-?


    Technology is likely to play an increasingly important role in the delivery of healthcare as the disparity between provider availability/expertise and patient numbers/needs increases. This article is intended to lend insight into the ways in which technology can facilitate the evaluation of patients with headache disorders and improve the ongoing monitoring of disease progression and response to therapy, following proper diagnosis. While it is not possible to prognosticate the impact of technologies not yet available, the article addresses potential novel usage of currently existing technology to standardize intake, expedite evaluations, ensure adequate history and documentation, and monitoring of patient care.

    View details for DOI 10.1007/s11940-017-0462-5

    View details for PubMedID 28536899

  • Complex regional pain syndrome is associated with structural abnormalities in pain-related regions of the human brain. journal of pain Barad, M. J., Ueno, T., Younger, J., Chatterjee, N., Mackey, S. 2014; 15 (2): 197-203


    Complex regional pain syndrome (CRPS) is a chronic condition that involves significant hyperalgesia of the affected limb, typically accompanied by localized autonomic abnormalities and frequently by motor dysfunction. Although central brain systems are thought to play a role in the development and maintenance of CRPS, these systems have not been well characterized. In this study, we used structural magnetic resonance imaging to characterize differences in gray matter volume between patients with right upper extremity CRPS and matched controls. Analyses were carried out using a whole brain voxel-based morphometry approach. The CRPS group showed decreased gray matter volume in several pain-affect regions, including the dorsal insula, left orbitofrontal cortex, and several aspects of the cingulate cortex. Greater gray matter volume in CRPS patients was seen in the bilateral dorsal putamen and right hypothalamus. Correlation analyses with self-reported pain were then performed on the CRPS group. Pain duration was associated with decreased gray matter in the left dorsolateral prefrontal cortex. Pain intensity was positively correlated with volume in the left posterior hippocampus and left amygdala, and negatively correlated with the bilateral dorsolateral prefrontal cortex. Our findings demonstrate that CRPS is associated with abnormal brain system morphology, particularly pain-related sensory, affect, motor, and autonomic systems.This paper presents structural changes in the brains of patients with CRPS, helping us differentiate CRPS from other chronic pain syndromes and furthering our understanding of this challenging disease.

    View details for DOI 10.1016/j.jpain.2013.10.011

    View details for PubMedID 24212070

  • Human Response to Unintended Intrathecal Injection of Botulinum Toxin PAIN MEDICINE Carroll, I., Fischbein, N., Barad, M., Mackey, S. 2011; 12 (7): 1094-1097


    Describe the first reported human intrathecal (IT) botulinum toxin injection.Case report.We report here the sequelae to an unintended IT injection of botulinum toxin type B (BTB) in a 60-year-old woman with chronic back pain.Following the IT administration of BTB, the patient experienced the onset of symmetric ascending stocking distribution painful dysesthesias, which persisted for approximately 6 months before receding. Objective neurologic deficits were not appreciated, and analgesic effects were prominently absent.Analgesic actions of botulinum toxins in animals and in humans have led to speculation that IT botulinum toxin might exert significant analgesic effects. The unusual and unexpected subsequent clinical course, neurologic sequelae, dysesthesias, and absence of analgesia suggest that botulinum toxin will not be a therapeutic modality to treat pain as proposed by those studying botulinum toxin in animal models.

    View details for DOI 10.1111/j.1526-4637.2011.01135.x

    View details for Web of Science ID 000292697100016

    View details for PubMedID 21627762

  • Serratus muscle stimulation effectively treats notalgia paresthetica caused by long thoracic nerve dysfunction: a case series. Journal of brachial plexus and peripheral nerve injury Wang, C. K., Gowda, A., Barad, M., Mackey, S. C., Carroll, I. R. 2009; 4: 17-?


    Currently, notalgia paresthetica (NP) is a poorly-understood condition diagnosed on the basis of pruritus, pain, or both, in the area medial to the scapula and lateral to the thoracic spine. It has been proposed that NP is caused by degenerative changes to the T2-T6 vertebrae, genetic disposition, or nerve entrapment of the posterior rami of spinal nerves arising at T2-T6. Despite considerable research, the etiology of NP remains unclear, and a multitude of different treatment modalities have correspondingly met with varying degrees of success. Here we demonstrate that NP can be caused by long thoracic nerve injury leading to serratus anterior dysfunction, and that electrical muscle stimulation (EMS) of the serratus anterior can successfully and conservatively treat NP. In four cases of NP with known injury to the long thoracic nerve we performed transcutaneous EMS to the serratus anterior in an area far lateral to the site of pain and pruritus, resulting in significant and rapid pain relief. These findings are the first to identify long thoracic nerve injury as a cause for notalgia paresthetica and electrical muscle stimulation of the serratus anterior as a possible treatment, and we discuss the implications of these findings on better diagnosing and treating notalgia paresthetica.

    View details for DOI 10.1186/1749-7221-4-17

    View details for PubMedID 19772656

    View details for PubMedCentralID PMC2758879